Hence, ATM is required for PDGFRA overexpression in both murine and human GBM cells, and combined inhibition of ATM and PDGFR induces lethality in TP53-mutant glioma cells, promising new opportunities for future GBM treatment. Here, TP53 is linked to glioma.